Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
GSK and Genmab receive accelerated approval for Arzerra™
Today, GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced the accelerated approval of Arzerra TM (ofatumumab).
Pandemic (H1N1) 2009 Influenza Update: Experience of GSK’s H1N1 adjuvanted vaccine, Pandemrix™, and preliminary paediatric results
GSK today announced that, to date, more than 150,000 people have received GSK pandemic H1N1 vaccine, Pandemrix.
FDA approves GlaxoSmithKline’s Votrient™ for advanced renal cell cancer
GSK announced that FDA has approved Votrient to treat patients with advanced renal cell carcinoma (RCC).
GlaxoSmithKline and Human Genome Sciences announce full presentation at ACR of positive phase 3 study results for Benlysta in systemic lupus erythematosus
Benlysta (belimumab) significantly reduced SLE disease activity, disease flare rates and fatigue; delayed time-to-first SLE disease flare.
GSK’s Cervarix® becomes the first cervical cancer vaccine to gain approval in Japan
Landmark approval paves the way for access to the vaccine for women in Japan
Pandemic (H1N1) 2009 Influenza Update: Results from second clinical trial of GSK’s H1N1 adjuvanted vaccine confirm immune response and tolerability
GSK announced results from a second clinical trial of its pandemic (H1N1) adjuvanted vaccine.
FDA approves Cervarix, GlaxoSmithKline’s cervical cancer vaccine
GSK announced today that FDA has approved Cervarix[Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant].
GSK partners with UK Government and Wellcome Trust to stimulate innovation through the creation of a world-class science park
GSK announced today the U.S. Food and Drug Administration (FDA) has not yet completed the review of the Biologics License Application.
GlaxoSmithKline and Prosensa form alliance to fight Duchenne Muscular Dystrophy
GlaxoSmithKline plc (GSK) announced today that it has entered into a unique partnership with the UK Government.
GSK’s Avodart® / tamsulosin combination showed benefits for men with prostate enlargement
GSK announced today that it has filed a sNDA for Avodart with the FDA for prostate cancer among men at increased of developing the disease.
GlaxoSmithKline and U.S. Patent and Trademark Office file a motion to dismiss litigation over Final Regulations
GSK and Prosensa, the Dutch based biopharmaceutical company focusing on RNA modulating therapeutics.
GlaxoSmithKline update: Government orders for pandemic (H1N1) 2009 vaccine
GSK is committed to supporting governments and health authorities around the world respond to the pandemic (H1N1) 2009 influenza strain.
GlaxoSmithKline receives unanimous FDA Panel approval recommendation for Votrient™
the panel voted that the benefit-to-risk profile is acceptable for patients with advanced renal cell carcinoma (RCC).
Positive phase II results for GSK1838262 (XP13512) reported for subjects with post-herpetic neuralgia and a history of inadequate response to gabapentin
GSK & XNPT announced results from a Phase II clinical trial of gabapentin enacarbil in adult patients with neuropathic pain from PHN.
GSK expands presence in China through strategic cooperation to form a joint venture on paediatric vaccines
GlaxoSmithKline (GSK) and Jiangsu Walvax Biotech Company today announced a cooperation agreement to form a long-term Joint Venture (JV)
Avodart (dutasteride) regulatory update
GSK filed a sNDA for Avodart with theFDA for prostate cancer risk reduction among men at increased risk of developing the disease.
Pandemic (H1N1) 2009 Influenza Update: GSK’s H1N1 ‘Pandemrix’ vaccine receives European Commission Approval
GlaxoSmithKline (GSK) confirmed today that the European Commission has granted marketing authorisation of GSK’s pandemic (H1N1).
GlaxoSmithKline update on FDA review of Cervarix
GSK announced the FDA has not yet completed the review of BLA for CERVARIX vaccine, review will continue beyond September 29, 2009.
Fatality reported in UK HPV vaccine immunisation programme
GSK notified of the death of 14 year old Natalie Morton, vaccinated in Coventry with Cervarix part of national HPV immunisation programme
GSK provides update on regulatory filings for Zunrisa/Rezonic
GSK to discontinue casopitant, developed for chemotherapy-induced and post-operative nausea and vomiting.